DOI:
10.1055/s-00000069
Seminars in Liver Disease
LinksClose Window
References
Reesink HW, Zeuzem S, Weegink CJ. et al.
Final results of a phase 1b, multiple-dose study of VX-950, a hepatitis C virus protease inhibitor
Hepatology 2005; 42: 234A-
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.